Smalley KSM - Search Results

1

Drepmel-A Multi-Omics Melanoma Drug Repurposing Resource for Prioritizing Drug Combinations and Understanding Tumor Microenvironment.

Thompson ZJ, Teer JK, Li J, Chen Z, Welsh EA, Zhang Y, Ayoubi N, Eroglu Z, Tan AC, Smalley KSM, Chen YA. Thompson ZJ, et al. Among authors: smalley ksm. Cells. 2022 Sep 16;11(18):2894. doi: 10.3390/cells11182894. Cells. 2022. PMID: 36139469 Free PMC article.

2

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.

Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL, Smalley KS. Paraiso KH, et al. Cancer Res. 2011 Apr 1;71(7):2750-60. doi: 10.1158/0008-5472.CAN-10-2954. Epub 2011 Feb 11. Cancer Res. 2011. PMID: 21317224 Free PMC article.

3

Fibroblasts contribute to melanoma tumor growth and drug resistance.

Flach EH, Rebecca VW, Herlyn M, Smalley KS, Anderson AR. Flach EH, et al. Mol Pharm. 2011 Dec 5;8(6):2039-49. doi: 10.1021/mp200421k. Epub 2011 Nov 8. Mol Pharm. 2011. PMID: 22067046 Free PMC article.

4

The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.

Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS. Paraiso KH, et al. Clin Cancer Res. 2012 May 1;18(9):2502-14. doi: 10.1158/1078-0432.CCR-11-2612. Epub 2012 Feb 20. Clin Cancer Res. 2012. PMID: 22351686 Free PMC article.

5

Targeted therapy in melanoma.

Kudchadkar RR, Smalley KS, Glass LF, Trimble JS, Sondak VK. Kudchadkar RR, et al. Clin Dermatol. 2013 Mar-Apr;31(2):200-8. doi: 10.1016/j.clindermatol.2012.08.013. Clin Dermatol. 2013. PMID: 23438383 Review.

6

Beyond BRAF: where next for melanoma therapy?

Fedorenko IV, Gibney GT, Sondak VK, Smalley KS. Fedorenko IV, et al. Br J Cancer. 2015 Jan 20;112(2):217-26. doi: 10.1038/bjc.2014.476. Epub 2014 Sep 2. Br J Cancer. 2015. PMID: 25180764 Free PMC article. Review.

7

XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation.

Phadke M, Gibney GT, Rich CJ, Fedorenko IV, Chen YA, Kudchadkar RR, Sondak VK, Weber J, Messina JL, Smalley KSM. Phadke M, et al. Among authors: smalley ksm. J Invest Dermatol. 2015 Oct;135(10):2542-2544. doi: 10.1038/jid.2015.205. Epub 2015 Jun 3. J Invest Dermatol. 2015. PMID: 26039542 Free PMC article. No abstract available.

8

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.

Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS. Fedorenko IV, et al. Oncogene. 2016 Mar 10;35(10):1225-35. doi: 10.1038/onc.2015.188. Epub 2015 Jun 15. Oncogene. 2016. PMID: 26073081 Free PMC article.

9

Combination Therapies for Melanoma: A New Standard of Care?

Smalley KS, Eroglu Z, Sondak VK. Smalley KS, et al. Am J Clin Dermatol. 2016 Apr;17(2):99-105. doi: 10.1007/s40257-016-0174-8. Am J Clin Dermatol. 2016. PMID: 26860106 Free PMC article. Review.

10

Improving patient outcomes to targeted therapies in melanoma.

Eroglu Z, Smalley KS, Sondak VK. Eroglu Z, et al. Expert Rev Anticancer Ther. 2016 Jun;16(6):633-41. doi: 10.1080/14737140.2016.1178575. Epub 2016 May 12. Expert Rev Anticancer Ther. 2016. PMID: 27137746 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

198 results

Search Page